Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source | Zendy

Robert G. Hart | Zendy; Mukul Sharma | Zendy; Hardi Mundl | Zendy; Scott E. Kasner | Zendy; Shrikant I. Bangdiwala | Zendy; Scott D. Berkowitz | Zendy; Balakumar Swaminathan | Zendy; Pablo M. Lavados | Zendy; Yongjun Wang | Zendy; Yilong Wang | Zendy; Antonio Dávalos | Zendy; N. А. Shamalov | Zendy; Robert Mikulík | Zendy; Luís Cunha | Zendy; Arne Lindgren | Zendy; Antonio Araúz | Zendy; Wilfried Lang | Zendy; Anna Członkowska | Zendy; Jens Eckstein | Zendy; Rubens José Gagliardi | Zendy; Pierre Amarenco | Zendy; Sebastián F. Ameriso | Zendy; Turgut Tatlisumak | Zendy; Roland Veltkamp | Zendy; Graeme J. Hankey | Zendy; Danilo Toni | Zendy; Dániel Bereczki | Zendy; Shinichiro Uchiyama | Zendy; George Ntaios | Zendy; ByungWoo Yoon | Zendy; Raf Brouns | Zendy; Matthias Endres | Zendy; Keith W. Muir | Zendy; Natan M. Bornstein | Zendy; Şerefnur Öztürk | Zendy; Martin O’Donnell | Zendy; Matthys M. De Vries Basson | Zendy; Guillaume Paré | Zendy; Calin Pater | Zendy; Bodo Kirsch | Zendy; Patrick Sheridan | Zendy; Gary Peters | Zendy; Jeffrey I. Weitz | Zendy; W. Frank Peacock | Zendy; Ashkan Shoamanesh | Zendy; Oscar Benavente | Zendy; Campbell Joyner | Zendy; Ellison Themeles | Zendy; Stuart J. Connolly | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

Author(s) -

Robert G. Hart,

Mukul Sharma,

Hardi Mundl,

Scott E. Kasner,

Shrikant I. Bangdiwala,

Scott D. Berkowitz,

Balakumar Swaminathan,

Pablo M. Lavados,

Yongjun Wang,

Yilong Wang,

Antonio Dávalos,

N. А. Shamalov,

Robert Mikulík,

Luís Cunha,

Arne Lindgren,

Antonio Araúz,

Wilfried Lang,

Anna Członkowska,

Jens Eckstein,

Rubens José Gagliardi,

Pierre Amarenco,

Sebastián F. Ameriso,

Turgut Tatlisumak,

Roland Veltkamp,

Graeme J. Hankey,

Danilo Toni,

Dániel Bereczki,

Shinichiro Uchiyama,

George Ntaios,

ByungWoo Yoon,

Raf Brouns,

Matthias Endres,

Keith W. Muir,

Natan M. Bornstein,

Şerefnur Öztürk,

Martin O’Donnell,

Matthys M. De Vries Basson,

Guillaume Paré,

Calin Pater,

Bodo Kirsch,

Patrick Sheridan,

Gary Peters,

Jeffrey I. Weitz,

W. Frank Peacock,

Ashkan Shoamanesh,

Oscar Benavente,

Campbell Joyner,

Ellison Themeles,

Stuart J. Connolly

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmc1809065

Subject(s) - rivaroxaban , medicine , aspirin , stroke (engine) , hazard ratio , embolism , warfarin , confidence interval , anesthesia , cardiology , atrial fibrillation , surgery , mechanical engineering , engineering

METHODS We compared the efficacy and safety of rivaroxaban (at a daily dose of 15 mg) with aspirin (at a daily dose of 100 mg) for the prevention of recurrent stroke in patients with recent ischemic stroke that was presumed to be from cerebral embolism but without arterial stenosis, lacune, or an identified cardioembolic source. The pri mary efficacy outcome was the first recurrence of ischemic or hemorrhagic stroke or systemic embolism in a timetoevent analysis; the primary safety outcome was the rate of major bleeding.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research